<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00319098</url>
  </required_header>
  <id_info>
    <org_study_id>107064</org_study_id>
    <secondary_id>107217</secondary_id>
    <nct_id>NCT00319098</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above</brief_title>
  <official_title>A Phase III, Observer-blind, Randomised Study to Evaluate the Safety and Immunogenicity of One and Two Administrations of Pandemic Monovalent (H5N1) Influenza Vaccine (Adjuvanted Split Virus Formulation) in Adults Aged 18 Years and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Today, the leading contender for the next pandemic of influenza is H5N1, a strain of avian
      virus. Prevention and control will depend on the rapid production and worldwide distribution
      of specific pandemic vaccines. Candidate 'pandemic-like' vaccines must be developed and
      tested in clinical trials to determine the most optimal formulation and the best vaccination
      schedule. This study is designed to test in healthy adults aged above 18 years the
      reactogenicity and immunogenicity of one and two administrations of a candidate pandemic H5N1
      vaccine formulated from Split Virus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study has 2 phases:

      The study ID 107064 corresponds to objectives &amp; outcome measures evaluated from day 0 until
      day 51.

      The study ID 107217 corresponds to objectives &amp; outcome measures evaluated at day 180.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2006</start_date>
  <completion_date type="Actual">July 31, 2007</completion_date>
  <primary_completion_date type="Actual">January 1, 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Solicited Local Symptoms</measure>
    <time_frame>During a 7 day follow-up period after each dose of vaccine and overall.</time_frame>
    <description>Assessed solicited local symptoms were ecchymosis, induration, pain, redness and swelling. Any = occurrence of symptom regardless of intensity grade. Grade 3 Pain = pain that prevented normal everyday activities Grade 3 ecchymosis/induration/redness/swelling = redness/swelling spreading beyond (&gt;) 50 millimeters (mm) in diameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Solicited General Symptoms (Dose 1)</measure>
    <time_frame>During the 7-day (Days 0-6) after Dose 1</time_frame>
    <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)], headache, myalgia, shivering, sweating. Any = occurrence of symptom regardless of intensity grade and relationship to vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 Fever = fever higher than (&gt;) 39.0 °C. Related = symptom considered by the investigator to be casually related with the study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Solicited General Symptoms (Dose 2)</measure>
    <time_frame>During the 7-day (Days 0-6) after Dose 2</time_frame>
    <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)], headache, myalgia, shivering, sweating. Any = occurrence of symptom regardless of intensity grade and relationship to vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 Fever = fever higher than (&gt;) 39.0 °C. Related = symptom considered by the investigator to be casually related with the study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Solicited General Symptoms (Across Doses)</measure>
    <time_frame>During the 7-day (Days 0-6) post vaccination across dosses</time_frame>
    <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)], headache, myalgia, shivering, sweating. Any = occurrence of symptom regardless of intensity grade and relationship to vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 Fever = fever higher than (&gt;) 39.0 °C. Related = symptom considered by the investigator to be casually related with the study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During the 21st Day (Days 0-20) post Dose 1</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. Related symptoms were not available.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With AEs</measure>
    <time_frame>During the 30 Day (Days 0-29) post Dose 2</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. Related symptoms were not available.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Day 0 to Day 180</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With New Onset Chronic Diseases (NOCDs)</measure>
    <time_frame>From Day 0 to Day 180</time_frame>
    <description>NOCDs include autoimmune disorders, asthma, type I diabetes, allergies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Medically Significant Conditions (MSCs)</measure>
    <time_frame>From Day 0 to Day 51</time_frame>
    <description>MSCs prompting emergency room or physician visits that were not related to common diseases or routine visits. Common diseases included upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti- Haemagglutinin Antibody (Anti-HA) Titers Against Avian Influenza A Subtype H5N1</measure>
    <time_frame>At Day 0 (PRE), 21 and 42</time_frame>
    <description>Anti-HA antibody titers were expressed as Geometric Mean Tiyers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects Against H5N1</measure>
    <time_frame>At Day 21 and Day 42</time_frame>
    <description>Seroconversion rate for Haemagglutinin antibody response was defined as the number of vaccinees who had either a pre-vaccination titer lower than (&lt;) 1:10 and a post-vaccination titer greater than or equal to (≥) 1:40 or a pre-vaccination titer ≥ 1:10 and at least a fourfold increase in post-vaccination titer. Seroconversion rate for Neutralising antibody response was defined as the percentage of vaccinees with a minimum 4-fold increase in titer at post-vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/Vietnam Influenza Strain</measure>
    <time_frame>At Day 21 and Day 42</time_frame>
    <description>Seroconversion factor was defined as the fold increase in serum HI GMTs post-vaccination compared to day 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against A/Vietnam Influenza Strain</measure>
    <time_frame>At Day 0 (PRE), Day 21 and Day 42</time_frame>
    <description>Seroprotection rate was defined as the number of vaccinees with a serum HI titer ≥1:40 that usually is accepted as indicating protection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5075</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>GSK1562902A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male and female subjects aged 18 or over received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm. The group was further stratified by age for analyses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix+Placebo Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Male and female subjects aged 18 or over received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm. The group was further stratified by age for analyses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted pandemic influenza candidate vaccine</intervention_name>
    <description>2 doses, intramuscular injection</description>
    <arm_group_label>GSK1562902A Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix</intervention_name>
    <description>One intramuscular injection</description>
    <arm_group_label>Fluarix+Placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One intramuscular injection</description>
    <arm_group_label>Fluarix+Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that they can and will comply with the
             requirements of the protocol.

          -  A male or female aged 18 years or above at the time of the first vaccination.

          -  Written informed consent obtained from the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

          -  If the subject is female, she must be of non-childbearing potential, for 30 days prior
             to first vaccination, have a negative pregnancy test and must agree to continue such
             precautions for two months after completion of the vaccination series.

        Exclusion Criteria:

          -  Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or
             4 weeks (for live vaccines) prior to enrolment in this study. Planned administration
             of a vaccine not foreseen by the study protocol up to 30 days after the second
             vaccination.

          -  Administration of interpandemic influenza vaccine between Day 0 and Day 51of the
             study. Those study participants belonging to risk groups eligible to receive the
             annual interpandemic influenza vaccine (in accordance with local regulations) can
             receive the annual vaccination after day 51 and before the end of the study on Day
             180.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within 6 months prior to the first administration of the study
             vaccine.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination

          -  History of chronic alcohol consumption and/or drug abuse.

          -  History of hypersensitivity to vaccines.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine.

          -  Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional
             abnormality, as determined by physical examination or laboratory screening tests.

          -  Major congenital defects or serious chronic disease including any medically
             significant chronic pulmonary, cardiovascular, renal, neurological, psychiatric or
             metabolic disorder, as determined by medical history and physical examination.
             (Subjects suffering from seasonal allergies or asthma under inhalative treatment can
             be included).

          -  Acute disease at the time of enrolment.

          -  Administration of immunoglobulins and/or any blood products within the 3 months
             preceding the first administration of the study vaccine or during the study.

          -  Lactating women

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days prior to the first vaccination, or planned use during
             the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tartu</city>
        <zip>50417</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Caen cedex 4</city>
        <zip>14052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lagord</city>
        <zip>17140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris Cedex 18</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rouen</city>
        <zip>76100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80799</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81667</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schwerin</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30519</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Witten</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58455</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04229</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3011 EN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620078</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kazan</city>
        <zip>420015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Novokuznetsk</city>
        <zip>654063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eskilstuna</city>
        <zip>SE-631 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2006</study_first_submitted>
  <study_first_submitted_qc>April 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2006</study_first_posted>
  <results_first_submitted>January 31, 2017</results_first_submitted>
  <results_first_submitted_qc>April 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 3, 2017</results_first_posted>
  <last_update_submitted>April 21, 2017</last_update_submitted>
  <last_update_submitted_qc>April 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adjuvanted pandemic influenza candidate vaccine</keyword>
  <keyword>Influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>107064</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107064</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107064</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107064</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107064</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register. The results of this study 107064 are summarised with study 107217 on the GSK Clinical Study Register.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107064</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Out of the 5075 subjects enrolled in this study, 4 subjects did not receive any study vaccine and were hence excluded from study start.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK1562902A Group</title>
          <description>Male and female subjects aged 18 or over received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm. The group was further stratified by age for analyses.</description>
        </group>
        <group group_id="P2">
          <title>Fluarix+Placebo Group</title>
          <description>Male and female subjects aged 18 or over received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm. The group was further stratified by age for analyses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3802"/>
                <participants group_id="P2" count="1269"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3667"/>
                <participants group_id="P2" count="1237"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Serious adverse event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Migrated/moved from study area</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Others</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK1562902A 18-60 YOA Group</title>
          <description>Male and female subjects 18-60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
        </group>
        <group group_id="B2">
          <title>GSK1562902A &gt;60 YOA Group</title>
          <description>Male and female subjects over (&gt;) 60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
        </group>
        <group group_id="B3">
          <title>Fluarix+Placebo 18-60 YOA Group</title>
          <description>Male and female subjects 18-60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
        </group>
        <group group_id="B4">
          <title>Fluarix+Placebo &gt;60 YOA Group</title>
          <description>Male and female subjects over (&gt;) 60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3397"/>
            <count group_id="B2" value="405"/>
            <count group_id="B3" value="1136"/>
            <count group_id="B4" value="133"/>
            <count group_id="B5" value="5071"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.8" spread="12.24"/>
                    <measurement group_id="B2" value="67.3" spread="6.01"/>
                    <measurement group_id="B3" value="35.4" spread="12.51"/>
                    <measurement group_id="B4" value="66.6" spread="5.20"/>
                    <measurement group_id="B5" value="38.36" spread="15.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2018"/>
                    <measurement group_id="B2" value="187"/>
                    <measurement group_id="B3" value="691"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="2952"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1379"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="445"/>
                    <measurement group_id="B4" value="77"/>
                    <measurement group_id="B5" value="2119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Solicited Local Symptoms</title>
        <description>Assessed solicited local symptoms were ecchymosis, induration, pain, redness and swelling. Any = occurrence of symptom regardless of intensity grade. Grade 3 Pain = pain that prevented normal everyday activities Grade 3 ecchymosis/induration/redness/swelling = redness/swelling spreading beyond (&gt;) 50 millimeters (mm) in diameter</description>
        <time_frame>During a 7 day follow-up period after each dose of vaccine and overall.</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort (TVc) which included all vaccinated subjects for whom data were available and with the symptom sheet filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix+Placebo 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix+Placebo &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local Symptoms</title>
          <description>Assessed solicited local symptoms were ecchymosis, induration, pain, redness and swelling. Any = occurrence of symptom regardless of intensity grade. Grade 3 Pain = pain that prevented normal everyday activities Grade 3 ecchymosis/induration/redness/swelling = redness/swelling spreading beyond (&gt;) 50 millimeters (mm) in diameter</description>
          <population>The analysis was performed on the Total Vaccinated cohort (TVc) which included all vaccinated subjects for whom data were available and with the symptom sheet filled in.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3343"/>
                <count group_id="O2" value="403"/>
                <count group_id="O3" value="1123"/>
                <count group_id="O4" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Ecchymosis, Dose 1 [N=3342;403;1123;133]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Ecchymosis, Dose 1[N=3342;403;1123;133]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Induration, Dose 1[N=3342;403;1123;133]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="876"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="199"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Induration, Dose 1[N=3342;403;1123;133]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Dose 1[N=3342;403;1123;133]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2926"/>
                    <measurement group_id="O2" value="233"/>
                    <measurement group_id="O3" value="724"/>
                    <measurement group_id="O4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 1[N=3342;403;1123;133]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 1[N=3342;403;1123;133]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="910"/>
                    <measurement group_id="O2" value="112"/>
                    <measurement group_id="O3" value="281"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 1[N=3342;403;1123;133]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 1[N=3342;403;1123;133]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="812"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="176"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 1[N=3342;403;1123;133]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Ecchymosis, Dose 2 [N=3247;395;1102;132]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Ecchymosis, Dose 2 [N=3247;395;1102;132]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Induration, Dose 2 [N=3247;395;1102;132]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="734"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Induration, Dose 2 [N=3247;395;1102;132]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Dose 2 [N=3247;395;1102;132]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2451"/>
                    <measurement group_id="O2" value="199"/>
                    <measurement group_id="O3" value="173"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 2 [N=3247;395;1102;132]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 2 [N=3247;395;1102;132]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="819"/>
                    <measurement group_id="O2" value="105"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 2 [N=3247;395;1102;132]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 2 [N=3247;395;1102.132]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="719"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 2 [N=3247;395;1102;132]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Ecchymosis, Across [N=3343;403;1123;133]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Ecchymosis, Across [N=3343;403;1123;133]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Induration, Across [N=3343;403;1123;133]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1150"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="215"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Induration, Across [N=3343;403;1123;133]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Across [N=3343;403;1123;133]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3037"/>
                    <measurement group_id="O2" value="271"/>
                    <measurement group_id="O3" value="748"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Across [N=3343;403;1123;133]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Across [N=3343;403;1123;133]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1277"/>
                    <measurement group_id="O2" value="165"/>
                    <measurement group_id="O3" value="312"/>
                    <measurement group_id="O4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Across [N=3343;403;1123;133]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Across [N=3343;1123;133]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1107"/>
                    <measurement group_id="O2" value="133"/>
                    <measurement group_id="O3" value="196"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Across [N=3343;1123;133]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Solicited General Symptoms (Dose 1)</title>
        <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)], headache, myalgia, shivering, sweating. Any = occurrence of symptom regardless of intensity grade and relationship to vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 Fever = fever higher than (&gt;) 39.0 °C. Related = symptom considered by the investigator to be casually related with the study vaccination.</description>
        <time_frame>During the 7-day (Days 0-6) after Dose 1</time_frame>
        <population>The analysis was performed on the TVc which included all vaccinated subjects for whom data were available and with the symptom sheet filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix+Placebo 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix+Placebo &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited General Symptoms (Dose 1)</title>
          <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)], headache, myalgia, shivering, sweating. Any = occurrence of symptom regardless of intensity grade and relationship to vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 Fever = fever higher than (&gt;) 39.0 °C. Related = symptom considered by the investigator to be casually related with the study vaccination.</description>
          <population>The analysis was performed on the TVc which included all vaccinated subjects for whom data were available and with the symptom sheet filled in.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3341"/>
                <count group_id="O2" value="403"/>
                <count group_id="O3" value="1123"/>
                <count group_id="O4" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Arthralgia, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="625"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Arthralgia, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Arthralgia, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="583"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="86"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1384"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="284"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1220"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="235"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1159"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="275"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="960"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="203"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1336"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="239"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1249"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="220"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="482"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="448"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Sweating, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="481"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Sweating, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Sweating, Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="415"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Solicited General Symptoms (Dose 2)</title>
        <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)], headache, myalgia, shivering, sweating. Any = occurrence of symptom regardless of intensity grade and relationship to vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 Fever = fever higher than (&gt;) 39.0 °C. Related = symptom considered by the investigator to be casually related with the study vaccination.</description>
        <time_frame>During the 7-day (Days 0-6) after Dose 2</time_frame>
        <population>The analysis was performed on the TVc which included all vaccinated subjects for whom data were available and with the symptom sheet filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix+Placebo 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix+Placebo &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited General Symptoms (Dose 2)</title>
          <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)], headache, myalgia, shivering, sweating. Any = occurrence of symptom regardless of intensity grade and relationship to vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 Fever = fever higher than (&gt;) 39.0 °C. Related = symptom considered by the investigator to be casually related with the study vaccination.</description>
          <population>The analysis was performed on the TVc which included all vaccinated subjects for whom data were available and with the symptom sheet filled in.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3246"/>
                <count group_id="O2" value="395"/>
                <count group_id="O3" value="1102"/>
                <count group_id="O4" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Arthralgia, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="513"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Arthralgia, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Arthralgia, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="493"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1108"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="148"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1014"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="119"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="934"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="155"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="800"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="111"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1044"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="999"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="390"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Sweating, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="442"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Sweating, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Sweating, Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="397"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Solicited General Symptoms (Across Doses)</title>
        <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)], headache, myalgia, shivering, sweating. Any = occurrence of symptom regardless of intensity grade and relationship to vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 Fever = fever higher than (&gt;) 39.0 °C. Related = symptom considered by the investigator to be casually related with the study vaccination.</description>
        <time_frame>During the 7-day (Days 0-6) post vaccination across dosses</time_frame>
        <population>The analysis was performed on the TVc which included all vaccinated subjects for whom data were available and with the symptom sheet filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix+Placebo 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix+Placebo &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited General Symptoms (Across Doses)</title>
          <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)], headache, myalgia, shivering, sweating. Any = occurrence of symptom regardless of intensity grade and relationship to vaccination. Grade 3 symptom = symptoms that prevented normal activity. Grade 3 Fever = fever higher than (&gt;) 39.0 °C. Related = symptom considered by the investigator to be casually related with the study vaccination.</description>
          <population>The analysis was performed on the TVc which included all vaccinated subjects for whom data were available and with the symptom sheet filled in.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3342"/>
                <count group_id="O2" value="403"/>
                <count group_id="O3" value="1123"/>
                <count group_id="O4" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Arthralgia, Across</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="874"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="130"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Arthralgia, Across</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Arthralgia, Across</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="829"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="112"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue, Across</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1736"/>
                    <measurement group_id="O2" value="117"/>
                    <measurement group_id="O3" value="346"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue, Across</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue, Across</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1576"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="289"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever, Across</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="466"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever, Across</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever, Across</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="432"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache, Across</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1566"/>
                    <measurement group_id="O2" value="114"/>
                    <measurement group_id="O3" value="350"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache, Across</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache, Across</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1347"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="266"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia, Across</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1670"/>
                    <measurement group_id="O2" value="124"/>
                    <measurement group_id="O3" value="276"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia, Across</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia, Across</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1593"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="249"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering, Across</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="711"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="86"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering, Across</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering, Across</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="675"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Sweating, Across</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="727"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="134"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Sweating, Across</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Sweating, Across</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="649"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="102"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. Related symptoms were not available.</description>
        <time_frame>During the 21st Day (Days 0-20) post Dose 1</time_frame>
        <population>The analysis was performed on the TVc which included all vaccinated subjects for whom data were available and with the symptom sheet filled in at Day 51.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix+Placebo 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix+Placebo &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. Related symptoms were not available.</description>
          <population>The analysis was performed on the TVc which included all vaccinated subjects for whom data were available and with the symptom sheet filled in at Day 51.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3397"/>
                <count group_id="O2" value="405"/>
                <count group_id="O3" value="1136"/>
                <count group_id="O4" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="917"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="244"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With AEs</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. Related symptoms were not available.</description>
        <time_frame>During the 30 Day (Days 0-29) post Dose 2</time_frame>
        <population>The analysis was performed on the TVc which included all subjects who had received the second dose and for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix+Placebo 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix+Placebo &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With AEs</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. Related symptoms were not available.</description>
          <population>The analysis was performed on the TVc which included all subjects who had received the second dose and for whom data were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3267"/>
                <count group_id="O2" value="396"/>
                <count group_id="O3" value="1111"/>
                <count group_id="O4" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="644"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="180"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>From Day 0 to Day 180</time_frame>
        <population>The analysis was performed on the Vaccinated Cohort (Extended follow-up) which included all vaccinated subjects for whom data were available at Day 180.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix+Placebo 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix+Placebo &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The analysis was performed on the Vaccinated Cohort (Extended follow-up) which included all vaccinated subjects for whom data were available at Day 180.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3253"/>
                <count group_id="O2" value="390"/>
                <count group_id="O3" value="1102"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With New Onset Chronic Diseases (NOCDs)</title>
        <description>NOCDs include autoimmune disorders, asthma, type I diabetes, allergies.</description>
        <time_frame>From Day 0 to Day 180</time_frame>
        <population>The analysis was performed on the Vaccinated Cohort (Extended follow-up) which included all vaccinated subjects for whom data were available at Day 180.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix+Placebo 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix+Placebo &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With New Onset Chronic Diseases (NOCDs)</title>
          <description>NOCDs include autoimmune disorders, asthma, type I diabetes, allergies.</description>
          <population>The analysis was performed on the Vaccinated Cohort (Extended follow-up) which included all vaccinated subjects for whom data were available at Day 180.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3253"/>
                <count group_id="O2" value="390"/>
                <count group_id="O3" value="1102"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Medically Significant Conditions (MSCs)</title>
        <description>MSCs prompting emergency room or physician visits that were not related to common diseases or routine visits. Common diseases included upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.</description>
        <time_frame>From Day 0 to Day 51</time_frame>
        <population>The analysis was performed on the TVc which included all vaccinated subjects for whom data were available at Day 51.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix+Placebo 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix+Placebo &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Medically Significant Conditions (MSCs)</title>
          <description>MSCs prompting emergency room or physician visits that were not related to common diseases or routine visits. Common diseases included upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.</description>
          <population>The analysis was performed on the TVc which included all vaccinated subjects for whom data were available at Day 51.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3397"/>
                <count group_id="O2" value="405"/>
                <count group_id="O3" value="1136"/>
                <count group_id="O4" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti- Haemagglutinin Antibody (Anti-HA) Titers Against Avian Influenza A Subtype H5N1</title>
        <description>Anti-HA antibody titers were expressed as Geometric Mean Tiyers (GMTs).</description>
        <time_frame>At Day 0 (PRE), 21 and 42</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects of the immunogenicity subset for whom data concerning immunogenicity endpoint measures were available. This includes subjects for whom assay results were available after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix+Placebo 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix+Placebo &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti- Haemagglutinin Antibody (Anti-HA) Titers Against Avian Influenza A Subtype H5N1</title>
          <description>Anti-HA antibody titers were expressed as Geometric Mean Tiyers (GMTs).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects of the immunogenicity subset for whom data concerning immunogenicity endpoint measures were available. This includes subjects for whom assay results were available after vaccination.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="97"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>anti-HA, Pre [N=269;146;96;50]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O4" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HA, Day 21 [N=269;145;97;49]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" lower_limit="25.7" upper_limit="39.4"/>
                    <measurement group_id="O2" value="43.8" lower_limit="33.3" upper_limit="57.5"/>
                    <measurement group_id="O3" value="6.0" lower_limit="5.1" upper_limit="7.0"/>
                    <measurement group_id="O4" value="7.5" lower_limit="5.5" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HA, Day 42 [N=268;140;96;50]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="307.0" lower_limit="258.4" upper_limit="364.8"/>
                    <measurement group_id="O2" value="187.0" lower_limit="148.8" upper_limit="235.1"/>
                    <measurement group_id="O3" value="5.6" lower_limit="4.9" upper_limit="6.3"/>
                    <measurement group_id="O4" value="7.5" lower_limit="5.5" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects Against H5N1</title>
        <description>Seroconversion rate for Haemagglutinin antibody response was defined as the number of vaccinees who had either a pre-vaccination titer lower than (&lt;) 1:10 and a post-vaccination titer greater than or equal to (≥) 1:40 or a pre-vaccination titer ≥ 1:10 and at least a fourfold increase in post-vaccination titer. Seroconversion rate for Neutralising antibody response was defined as the percentage of vaccinees with a minimum 4-fold increase in titer at post-vaccination.</description>
        <time_frame>At Day 21 and Day 42</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects of the immunogenicity subset for whom data concerning immunogenicity endpoint measures were available. This includes subjects for whom assay results were available after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix+Placebo 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix+Placebo &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects Against H5N1</title>
          <description>Seroconversion rate for Haemagglutinin antibody response was defined as the number of vaccinees who had either a pre-vaccination titer lower than (&lt;) 1:10 and a post-vaccination titer greater than or equal to (≥) 1:40 or a pre-vaccination titer ≥ 1:10 and at least a fourfold increase in post-vaccination titer. Seroconversion rate for Neutralising antibody response was defined as the percentage of vaccinees with a minimum 4-fold increase in titer at post-vaccination.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects of the immunogenicity subset for whom data concerning immunogenicity endpoint measures were available. This includes subjects for whom assay results were available after vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>anti-HA, Day 21 [N=269;145;96;49]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HA, Day 42 [N=268;140;96;50]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                    <measurement group_id="O2" value="128"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/Vietnam Influenza Strain</title>
        <description>Seroconversion factor was defined as the fold increase in serum HI GMTs post-vaccination compared to day 0.</description>
        <time_frame>At Day 21 and Day 42</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects of the immunogenicity subset for whom data concerning immunogenicity endpoint measures were available. This includes subjects for whom assay results were available after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix+Placebo 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix+Placebo &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/Vietnam Influenza Strain</title>
          <description>Seroconversion factor was defined as the fold increase in serum HI GMTs post-vaccination compared to day 0.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects of the immunogenicity subset for whom data concerning immunogenicity endpoint measures were available. This includes subjects for whom assay results were available after vaccination.</population>
          <units>Titer fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Vietnam, Day 21 [N=269;145;96;49]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="5.1" upper_limit="7.9"/>
                    <measurement group_id="O2" value="8.8" lower_limit="6.7" upper_limit="11.5"/>
                    <measurement group_id="O3" value="1.2" lower_limit="1.0" upper_limit="1.4"/>
                    <measurement group_id="O4" value="1.5" lower_limit="1.1" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Vietnam, Day 21 [N=268;140;96;50]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.4" lower_limit="51.7" upper_limit="73.0"/>
                    <measurement group_id="O2" value="37.4" lower_limit="29.8" upper_limit="47.0"/>
                    <measurement group_id="O3" value="1.1" lower_limit="1.0" upper_limit="1.3"/>
                    <measurement group_id="O4" value="1.5" lower_limit="1.1" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against A/Vietnam Influenza Strain</title>
        <description>Seroprotection rate was defined as the number of vaccinees with a serum HI titer ≥1:40 that usually is accepted as indicating protection.</description>
        <time_frame>At Day 0 (PRE), Day 21 and Day 42</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects of the immunogenicity subset for whom data concerning immunogenicity endpoint measures were available. This includes subjects for whom assay results were available after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1562902A 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1562902A &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix+Placebo 18-60 YOA Group</title>
            <description>Male and female subjects 18-60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix+Placebo &gt;60 YOA Group</title>
            <description>Male and female subjects over (&gt;) 60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against A/Vietnam Influenza Strain</title>
          <description>Seroprotection rate was defined as the number of vaccinees with a serum HI titer ≥1:40 that usually is accepted as indicating protection.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects of the immunogenicity subset for whom data concerning immunogenicity endpoint measures were available. This includes subjects for whom assay results were available after vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="97"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Vietnam, PRE [N=269;146;96;50]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Vietnam, Day 21 [N=269;145;97;49]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Vietnam, Day 42 [N=268;140;96;50]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                    <measurement group_id="O2" value="128"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited local and general symptoms during the 7 days post-vaccination, Unsolicited AEs during the 21 post Dose 1 and 30 days post Dose 2; SAEs from Day 0 to Day 180.</time_frame>
      <desc>During the given time frame for unsolicited AEs, no symptom reached nor surpassed the 5% threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>GSK1562902A 18-60 YOA Group</title>
          <description>Male and female subjects 18-60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
        </group>
        <group group_id="E2">
          <title>GSK1562902A &gt;60 YOA Group</title>
          <description>Male and female subjects over (&gt;) 60 years of age (YOA) received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.</description>
        </group>
        <group group_id="E3">
          <title>Fluarix+Placebo 18-60 YOA Group</title>
          <description>Male and female subjects 18-60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
        </group>
        <group group_id="E4">
          <title>Fluarix+Placebo &gt;60 YOA Group</title>
          <description>Male and female subjects over (&gt;) 60 years of age (YOA) received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Cardiac valve</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Oesophageal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Genital injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Heat stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus noninsulindependent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Vitamin b12 deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Intra-uterine death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Premature rupture of membranes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Generalised anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bartholinís cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3037" subjects_at_risk="3343"/>
                <counts group_id="E2" subjects_affected="271" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="748" subjects_at_risk="1123"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="320" subjects_at_risk="3343"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="1123"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" subjects_affected="1150" subjects_at_risk="3343"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="215" subjects_at_risk="1123"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3037" subjects_at_risk="3343"/>
                <counts group_id="E2" subjects_affected="271" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="748" subjects_at_risk="1123"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="1277" subjects_at_risk="3343"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="312" subjects_at_risk="1123"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1107" subjects_at_risk="3343"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="196" subjects_at_risk="1123"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="874" subjects_at_risk="3342"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="130" subjects_at_risk="1123"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1736" subjects_at_risk="3342"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="346" subjects_at_risk="1123"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="466" subjects_at_risk="3342"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="1123"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1566" subjects_at_risk="3342"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="350" subjects_at_risk="1123"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1670" subjects_at_risk="3342"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="276" subjects_at_risk="1123"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" subjects_affected="711" subjects_at_risk="3342"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="1123"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="727" subjects_at_risk="3342"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="134" subjects_at_risk="1123"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

